Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus

Hiep L.X. Vu; Byungjoon Kwon; Marcelo de Lima; Asit K. Pattnaik; Fernando A. Osorio

doi:10.1016/j.vaccine.2013.07.020

Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus

Hiep L.X. Vu, Byungjoon Kwon, Marcelo de Lima, Asit K. Pattnaik, Fernando A. Osorio

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

DIVA (differentiating infected from vaccinated animals) vaccines have proven extremely useful for control and eradication of infectious diseases in livestock. We describe here the characterization of a serologic marker epitope, so-called epitope-M201, which can be a potential target for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Epitope-M201 is located at the carboxyl terminus (residues 161-174) of the viral M protein. The epitope is highly immunodominant and well-conserved among type-II PRRSV isolates. Rabbit polyclonal antibodies prepared against this epitope are non-neutralizing; thus, the epitope does not seem to contribute to the protective immunity against PRRSV infection. Importantly, the immunogenicity of epitope-M201 can be disrupted through the introduction of a single amino acid mutation which does not adversely affect the viral replication. All together, our results provide an important starting point for the development of a live-attenuated DIVA vaccine against type-II PRRSV.

Original language	English (US)
Pages (from-to)	4330-4337
Number of pages	8
Journal	Vaccine
Volume	31
Issue number	40
DOIs	https://doi.org/10.1016/j.vaccine.2013.07.020
State	Published - Sep 13 2013

Keywords

DIVA vaccines
M protein
PRRSV
Serological marker epitope

ASJC Scopus subject areas

Molecular Medicine
Immunology and Microbiology(all)
veterinary(all)
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2013.07.020

Cite this

@article{76fcb688fb014325b8047155fa82c68d,

title = "Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus",

abstract = "DIVA (differentiating infected from vaccinated animals) vaccines have proven extremely useful for control and eradication of infectious diseases in livestock. We describe here the characterization of a serologic marker epitope, so-called epitope-M201, which can be a potential target for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Epitope-M201 is located at the carboxyl terminus (residues 161-174) of the viral M protein. The epitope is highly immunodominant and well-conserved among type-II PRRSV isolates. Rabbit polyclonal antibodies prepared against this epitope are non-neutralizing; thus, the epitope does not seem to contribute to the protective immunity against PRRSV infection. Importantly, the immunogenicity of epitope-M201 can be disrupted through the introduction of a single amino acid mutation which does not adversely affect the viral replication. All together, our results provide an important starting point for the development of a live-attenuated DIVA vaccine against type-II PRRSV.",

keywords = "DIVA vaccines, M protein, PRRSV, Serological marker epitope",

author = "Vu, {Hiep L.X.} and Byungjoon Kwon and {de Lima}, Marcelo and Pattnaik, {Asit K.} and Osorio, {Fernando A.}",

note = "Funding Information: This research has been supported by grants from the University of Nebraska Life Sciences Competitive Grants Program (Facilitating UNL and Industry Partnerships 2011–2013) and from the National Pork Board of the U.S. (NPB 08-248). We thank Dr. Kyoung-Jin Yoon at Iowa State University – Veterinary Diagnostic Laboratory and by Dr. Tony Goldberg at School of Veterinary Medicine, University of Wisconsin-Madison for providing us the PRRSV field isolates. ",

year = "2013",

month = sep,

day = "13",

doi = "10.1016/j.vaccine.2013.07.020",

language = "English (US)",

volume = "31",

pages = "4330--4337",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "40",

}

TY - JOUR

T1 - Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus

AU - Vu, Hiep L.X.

AU - Kwon, Byungjoon

AU - de Lima, Marcelo

AU - Pattnaik, Asit K.

AU - Osorio, Fernando A.

N1 - Funding Information: This research has been supported by grants from the University of Nebraska Life Sciences Competitive Grants Program (Facilitating UNL and Industry Partnerships 2011–2013) and from the National Pork Board of the U.S. (NPB 08-248). We thank Dr. Kyoung-Jin Yoon at Iowa State University – Veterinary Diagnostic Laboratory and by Dr. Tony Goldberg at School of Veterinary Medicine, University of Wisconsin-Madison for providing us the PRRSV field isolates.

PY - 2013/9/13

Y1 - 2013/9/13

N2 - DIVA (differentiating infected from vaccinated animals) vaccines have proven extremely useful for control and eradication of infectious diseases in livestock. We describe here the characterization of a serologic marker epitope, so-called epitope-M201, which can be a potential target for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Epitope-M201 is located at the carboxyl terminus (residues 161-174) of the viral M protein. The epitope is highly immunodominant and well-conserved among type-II PRRSV isolates. Rabbit polyclonal antibodies prepared against this epitope are non-neutralizing; thus, the epitope does not seem to contribute to the protective immunity against PRRSV infection. Importantly, the immunogenicity of epitope-M201 can be disrupted through the introduction of a single amino acid mutation which does not adversely affect the viral replication. All together, our results provide an important starting point for the development of a live-attenuated DIVA vaccine against type-II PRRSV.

AB - DIVA (differentiating infected from vaccinated animals) vaccines have proven extremely useful for control and eradication of infectious diseases in livestock. We describe here the characterization of a serologic marker epitope, so-called epitope-M201, which can be a potential target for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus (PRRSV). Epitope-M201 is located at the carboxyl terminus (residues 161-174) of the viral M protein. The epitope is highly immunodominant and well-conserved among type-II PRRSV isolates. Rabbit polyclonal antibodies prepared against this epitope are non-neutralizing; thus, the epitope does not seem to contribute to the protective immunity against PRRSV infection. Importantly, the immunogenicity of epitope-M201 can be disrupted through the introduction of a single amino acid mutation which does not adversely affect the viral replication. All together, our results provide an important starting point for the development of a live-attenuated DIVA vaccine against type-II PRRSV.

KW - DIVA vaccines

KW - M protein

KW - PRRSV

KW - Serological marker epitope

UR - http://www.scopus.com/inward/record.url?scp=84882822947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882822947&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.07.020

DO - 10.1016/j.vaccine.2013.07.020

M3 - Article

C2 - 23892102

AN - SCOPUS:84882822947

SN - 0264-410X

VL - 31

SP - 4330

EP - 4337

JO - Vaccine

JF - Vaccine

IS - 40

ER -

Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this